VIRTUAL ANNUAL GENERAL MEETING 2021

June 22, 2021, at 2.00p.m.

Report of the Management Board on agenda item 1

I now hand over to the Chief Executive Officer, Prof. Sahin, for his report. Prof. Sahin is connected via video connection.

Report of the Management Board – Prof. Dr. Ugur Sahin, CEO

Dear ladies and gentlemen, shareholders and shareholder´s representatives,

(Slide 5) I would like to welcome you to BioNTech´s AGM 2021. Thank you for accepting our invitation even though the event can only take place virtually. I would have very much liked to welcome you in person today. But I am optimistic that it will be possible again next year. The reason I am optimistic is because of all that we and many other companies and partners have achieved over the past 18 months. In short, 2020 was a transformative year for BioNTech. A year that was very different compared to what we had expected or planned for our company.

At the beginning of 2020, the global community was faced with a new virus that put life as we know it to a halt. At BioNTech, we felt the duty to contribute to finding a solution. To this end, we started our vaccine development program “Project Lightspeed” in January 2020. We had the goal to develop a well-tolerated and effective COVID-19 vaccine as quickly as possible – without compromising quality. It was a true challenge: Making the impossible possible. We achieved this goal in only 10 months. This was the fastest development of an approved vaccine in the history of medicine.

This success is the result of decades of research we have invested in developing immunotherapies for cancer patients. It is also the result of the hard work and dedication of our team of experts from 60 nations that has worked day and night to turn this vision into a reality. I am proud and grateful at the same time to work with dedicated, inspiring people who help us transform our vision into reality.

When we founded BioNTech in 2008, we wanted to develop individualized cancer treatments, tailored to every individual patient. This was based on a profound scientific foundation and a vision of engineering immunity for serious diseases. We knew: Science can make a difference to people's lives. So we started on this foundation with early investors who believed in our vision. From the start, it was our goal to improve the health of people globally. And Project Lightspeed allowed us to turn that vision into reality for the first time.

Today, we want to give you an insight into BioNTech´s achievements over the last year and provide an outlook on what's next for BioNTech near- and long term.

(Slide 6) As stated on slide 6, we will make "forward looking statements" during this meeting that are subject to the risks and uncertainties discussed in detail in our filings, including our most recent annual report on Form 20-F, with the U.S. SEC. These statements, including without limitation, those regarding BioNTech's authorized or approved COVID-19 vaccine, our pipeline, and BioNTech's future financial performance, are based on management's current assumptions. Actual results could differ materially from those projected in such statements. All information in this presentation is as of its date, and BioNTech undertakes no duty to update this information.

Please see important indication and safety information for our COVID-19 vaccine on slides 7 and 8, which has been authorized or approved for emergency or temporary use or granted conditional marketing authorization in the U.S. and the EU, and many other countries globally.

Today, BioNTech is a fully integrated global immunotherapy powerhouse.

Our integrated structure includes our immunology expertise, novel technologies, a bioinformatics approach, in-house manufacturing, commercial capabilities and a global team of over 2,000 employees.

We believe that over 80% of all diseases are mediated by the immune system. Therefore, we see a huge potential for immunotherapies. We are developing next-generation immunotherapies and vaccines that are not limited to oncology and infectious diseases, but will also focus on other indications in the future.

More than half of our development programs are wholly owned by BioNTech, allowing us to keep the majority of the value we create from our efforts. Through our collaborations with a number of global pharmaceutical companies that include Roche/Genentech, Pfizer, Sanofi, Genmab and Regeneron, we can complement our competencies.

Building on our current momentum and cash position, we believe we have the potential to launch multiple products in the next five years.

Through the successful development of the first approved COVID-19 vaccine, and the concomitant establishment of mRNA as a new drug class globally, we were able to prove our innovative strength and our competencies to excel.

Our team along with our partner Pfizer developed and received approval for a safe and well-tolerated vaccine. To date, we have delivered more than 700 million doses to people in over 100 countries. We are already seeing signs of a positive impact on the trajectory of the pandemic in many countries, which is supported by real-world vaccination studies that confirm a significant drop in infections in the vaccinated population.

A global pandemic requires global solutions. That is why, very early on in our BNT162 program, we partnered with Pfizer and Fosun Pharma – Fosun to cover the Chinese Market, Pfizer to address the rest of the world. These partnerships enabled us to establish a global development program and distribution network. It remains our goal to deliver as many doses of our COVID-19 vaccine as possible to people around the world to help end this pandemic and facilitate the return to a normal life.

Ten days ago we announced plans to provide the U.S. government at a not-for-profit price 500 million doses with our COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. The U.S. government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them. These doses are part our previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and middle-income countries over the next 18 months.

BioNTech and Pfizer are now targeting a manufacturing capacity of up to 3 billion doses by the end of 2021 and more than 3 billion doses in 2022, with BioNTech contributing at least 50% of drug substance manufacturing.

As we continue to learn about emerging variants, our teams are rapidly responding to the dynamics of the pandemic by adapting technology, manufacturing and regulatory processes to ensure we continue to have a robust vaccine that protects humanity from COVID-19.

The demand for our vaccine remains high. We have a strong order book in place for 2021 with several contracts signed for 2022 and beyond. As of May 4th, BioNTech and Pfizer have secured

orders for approximately 1.8 billion doses of the vaccine to be delivered in 2021, which includes increased orders from the EU and Japan. We also have a contract to supply 900 million doses to the European Union for the years 2022 to 2023 with an option for an additional 900 million doses. This is a historic development as it is one of the largest supply contracts in the history of the pharmaceutical industry.

The extraordinary circumstances of the global pandemic, and our response to it certainly had a significant impact on BioNTech as a company, accelerating our development into a global, integrated biopharmaceutical company. We have received approval for emergency or temporary use, or conditional marketing authorization of our COVID-19 vaccine in more than 70 countries and regions. Through our collaboration with Fosun we are approaching approval of our vaccine for China. In Germany we successfully executed the commercial launch of our COVID-19 vaccine, which we distribute under the brand name Comirnaty, with our own sales team. Our Marburg manufacturing site, which we acquired last year, is becoming one of the largest mRNA vaccine manufacturing sites worldwide and with that site fully operational, BioNTech's standalone annual vaccine manufacturing capacity will be approximately 1 billion doses.

Although the development and production of a COVID-19 vaccine was the focus of our work last year, we have continued to drive the advancement of our robust pipeline in oncology and made significant progress: we now have 14 product candidates in 16 ongoing clinical trials. We thus have programs in clinical development across all four drug classes that we use in our oncology portfolio. This underlines our diversified approach to address a variety of diseases with different therapeutic modalities. To support our pipeline progress, we continue to increase our global footprint with new offices beyond our subsidiary in the United States, which was established through the acquisition of Neon Therapeutics in 2020. This includes our commercial subsidiaries in Germany, in Turkey, and the newest Southeast Asia regional headquarters in Singapore.

The exciting year we experienced in 2020 also yielded a number of important learnings and key insights of 2020 that demonstrate the disruptive potential of BioNTech’s approach. The COVID-19 vaccine development has shown the power of mRNA technology with regards to clinical efficacy and safety, speed in clinical development and scale-up of manufacturing capacities, underscoring the promise of this technology platform. Our established toolbox of mRNA technologies can support a diverse range of therapeutic and prophylactic platforms in different indications.

We believe that BioNTech's vast IP portfolio and comprehensive know-how in immunology, combined with ongoing investment in integrated infrastructure and R&D, positions the company to be a global leader in the mRNA-technology sector. Applying the capabilities developed during "Project Lightspeed", and adopting the proven development process we have the potential to rapidly advance additional innovative therapeutics and vaccines to the market. BioNTech's deep focus on innovation along with synergistic blue-chip collaborations enables our market-leading position while expanding internal capabilities.

As we look to the future and the rest of our pipeline, we believe that the validation of BioNTech's mRNA technology over the course of the last year will unlock an entirely new therapeutic universe. Our core mRNA technologies underpin many of our therapeutic platforms and provide an important building block for our company to address multiple disease areas beyond our preliminary focus areas of oncology and infectious disease. We believe our approaches could have significant impact on the areas of allergy, autoimmune and inflammatory diseases, as well as open up new opportunities in regenerative medicine.

Our aim is to replace traditional or existing therapies with new products with improved pharmacology and novel modes of action. This includes not only our mRNA technology but also our cell therapy and protein therapeutic approaches.

Our strategic priority for 2021 is to reinvest the capital from our successful vaccine to further drive innovation across different therapeutic areas and technologies as well as our corporate development to build long-term value for patients, shareholders and society.

We continue to increase our global footprint with new offices beyond our subsidiaries mentioned earlier. We are expanding our integrated infrastructure with additional strategic investments in scientific and technological innovation. This is in the heart of everything we do. These investments, which span clinical, commercial, manufacturing excellence, and include digital capabilities, will support future product launches.

Our success is driven by people. Therefore, attracting and developing top talent remains a crucial imperative for us.

We see a tremendous opportunity as we advance our robust pipeline in oncology and infectious diseases and expand into new therapeutic areas. Three potentially registrational Phase 2 trials are expected to start this year, of which we have just started the randomized Phase 2 trial with our FixVac program in melanoma. We are also advancing a number of our pre-clinical innovations

into first-in-human studies. In addition to our internal efforts, we will continue to evaluate external innovations to complement our pipeline.

Next, I would like to outline the broad spectrum of our COVID-19 vaccine activities. We remain focused on six key levers to expand the distribution of our COVID-19 vaccine. In 2021, we aim to provide the vaccine to over 1 billion people globally.

We have increased our manufacturing capacity to 3 billion doses for 2021 and expect to have capacity to exceed 3 billion doses in 2022. The first shipments from our Marburg facility were delivered mid-April, a remarkable accomplishment for BioNTech´s manufacturing scale-up efforts. In Singapore we are establishing a regional headquarter that will also include a highly automated and end-to-end mRNA manufacturing facility, further adding to our global manufacturing capacity.

To support label expansion into additional populations, we have an expansive global clinical program running. In this context, we have initiated a global Phase 2/3 trial in healthy pregnant women, and we recently initiated a trial in children between 6 months to 11 years. We expect to announce safety data from those studies in the third and fourth quarter 2021. The US FDA and the EMA also recently granted approval for label expansion in adolescents 12-15 years of age.

To decentralize vaccine access, we initiated the rolling Biologics License Application in the United States for our COVID-19 vaccine and will seek full approval of our vaccine in countries where regulatory submissions have been made and emergency use authorizations or equivalents are currently in place.

We continue to generate updated stability data of our current COVID-19 vaccine. Both the FDA and EMA have updated our label with two weeks' storage and transport at minus 25 to minus 15 degree Celsius and both agencies recently also approved storage period of unopened thawed vials at 2-8°C from five days to 31 days. In parallel, we are developing ready-to-use and lyophilized formulations with improved thermostability profiles.

Our understanding of SARS-CoV-2 is evolving as new data are generated, and we understand that immunity may wane over time and that new variants will emerge. While I do believe a booster will be of high value to reestablish full immunity, we do not know yet when and how frequently that will be required.

In order to be prepared and to be able to respond quickly in case a third dose or a strain adaptation will be required in the future we continue to monitor real-world efficacy of our vaccine as well as efficacy against emerging variants. Currently, there is no evidence that an adaptation of our

current vaccine against any of the circulating variants is necessary. For the past several months, we have been working on establishing a development, manufacturing and regulatory “prototype pathway” for modified COVID-19 vaccines. To sum up, these six focus areas secure our leading position in the COVID-19 vaccine arena.

As shown on slide 16, we are advancing multiple additional infectious disease programs. We are exploring a number of product candidates for HIV and tuberculosis supported by the Bill & Melinda Gates Foundation. Our research collaboration with the University of Pennsylvania focuses on up to 10 mRNA vaccine candidates for indications with high medical need. Through a licensing agreement with Pfizer, we are collaborating to develop an influenza vaccine. These programs are showing good progress in preclinical development, and we plan to initiate a first-in-human study for our influenza program in the third quarter of this year.

Now I would like to outline our immuno-oncology strategy, which is based on several first-in-class immunological therapeutic approaches designed to modulate the immune response to treat cancer. We use potentially high effective target molecules in combination with immune-modulatory drug substances. These address the unique molecular signature of each patient’s tumor with high precision. The multitude of different technologies and modes of action may have the potential to address a broad range of solid tumors in different disease stages.

We believe that harnessing complementary modes of action increases the likelihood of therapeutic success, for example in therapy resistant tumor types, and unlocks a larger potential market. Our diversified technologies are being further developed to address current therapy limitations and provide a pipeline of potentially combinable product candidates with synergistic modes of action.

One example is our CARVac approach. The product candidate BNT211 is one of our cell therapy-programs that is in clinical testing since beginning of this year. It combines our FixVac immunotherapy with our novel CAR-T therapies to potentially make the treatment of advanced solid tumors more potent and tolerable.

At this point, I would like to mention that we have seen some ongoing impact from the COVID-19 pandemic on our clinical operations in 2020 and 2021. Specifically, there has been a slowdown in the enrollment in some of our ongoing studies. Early in the pandemic, we put a 3-point plan in place to manage disruptions created by COVID-19. We focused on timely completion of ongoing trials and prioritized the initiation of phase 2 clinical trials. New phase 1 clinical trials were delayed

to 2021. Despite these constraints, we have initiated 5 new trials and we presented several datasets, which I will summarize now.

For our Next Generation Immunomodulator program BNT311, which is partnered with Genmab, we presented promising early Phase 1 data at the SITC conference 2020. At that same conference we also presented Phase 1 data for BNT131, our intratumoral immunotherapy product candidate, which is partnered with Sanofi.

For our FixVac product candidate BNT111 in melanoma, we published data from an exploratory data analysis from our ongoing Phase 1 trial in the medical journal Nature. BNT111 in monotherapy, and even more in combination with the checkpoint inhibitor anti-PD1, showed promising data in patients with advanced melanoma and a tolerable safety profile.

At the ESMO conference 2020, we presented early Phase 1 data for our FixVac product candidate BNT114, which is being tested in patients with triple negative breast cancer.

For our Individualized Neoantigen Specific Immunotherapy BNT122, or iNeST platform, we have a collaboration with Roche-Genentech. At the AACR conference 2020, we presented data from the phase 1 trial in patients with solid tumors. In the Unites States the application for a planned randomized Phase 2 trial in adjuvant colorectal cancer was approved and we plan to start this trial in the second half 2021.

In our Small Molecule Immunomodulator program of BNT411 in lung cancer the first patient was dosed in a Phase 1/2a trial in summer 2020.

(Slide 18) Now that I have outlined our significant progress across all of our oncology programs over the last year, let's turn our attention to our most advanced developments.

As already mentioned, we recently started a randomized Phase-2 trial for our FixVac product candidate BNT111 in advanced melanoma. For our second FixVac product candidate BNT113, an mRNA vaccine for HPV16 positive head and neck cancer, we expect to start a randomized Phase 2 trial soon.

For BNT122, the Phase 2 trial in first line treatment of metastatic melanoma and the Phase 1 basket trial in solid tumors, which I just mentioned, remain ongoing. Based on the mode-of-action and data seen for iNeST, we decided to move into adjuvant, early-disease treatment settings. Besides the Phase 2 trial in colorectal cancer, which I just outlined, we, together with Genentech, are evaluating other options for treating early-stage cancer patients with BNT122.

For our next-generation checkpoint immune modulator program, which is partnered with Genmab, we expect to provide a data update in the second half of 2021 for the ongoing Phase 1/2 trial of BNT311, which targets PD-L1 and 4-1BB. We remain encouraged by the results seen to date and believe this product has significant potential across multiple oncology indications, given the unmet need for improved checkpoint immunotherapies.

We also plan to present data in the second half of 2021 from our second program of this collaboration, BNT312.

Slide 19 provides an overview of our next-wave oncology assets, that have the potential to advance innovation beyond current boundaries. We already started three first-in-human phase 1 clinical trials in 2021 and expect to start three more this year.

“CARVac”, or BNT211, our first CAR-T-product candidate, entered clinical testing in February 2021. For the first product candidate from our individualized T cell therapy program, BNT221, a first in human trial study started in April 2021.

For BNT151, our first RiboCytokine product candidate encoding a modified IL-2, the first patient was dosed in a Phase 1 trial in solid tumors in February 2021. We plan to start a Phase 1 trial for BNT152 and BNT153, our IL-2, IL-7 ribocytokine combination, in the first half of 2021, and we also plan to start Phase 1 trials for the treatment of multiple solid tumors with our RiboMab therapies BNT141 and BNT142 in the second half of 2021.

With the significant R&D activity I’ve highlighted, we are expecting a year rich in clinical milestones, which are summarized on slide 20. In total, we have planned the start of 10 clinical trials in 2021, of which the first patient has already been dosed in 4 - including the randomized phase 2 trial of our FixVac program in melanoma. We remain on track to initiate two more randomized Phase 2 trials with our iNeST and FixVac programs.

In the second half of 2021, we expect data updates on up to five different programs.

In 2008, we set out to develop immunotherapies against cancer, tailor-made for a single individual. In 2020, our first approved product was an innovative vaccine, which had the potential to change the world. Now, we look forward to accelerating the development of potentially life-changing therapies across a broad range programs in the coming years.

As immune engineers and physicians, we will continue to pursue our vision of improving the health of people around the world by harnessing the full potential of the immune system.

The pandemic has taught us that we can make a difference in the lives of people across the world. Through courage paired with humility, professionalism paired with pragmatism and cooperation paired with acceptance of responsibility by the individual. These principles will continue to guide us in the future.

I look forward to taking these next steps in the development of our company together with you, our shareholders. Without your vision and conviction in the importance and power of science, "Project Lightspeed" would not have been possible. You are part of the reason, we were able to create the basis to build BioNTech into a global, fully integrated immunotherapy company. That is why I would like to thank you for all your support.

I would like to welcome Jens Holstein as new Chief Financial Officer, who will introduce himself briefly in a moment. Going forward, Sierk Poetting will focus his efforts on his role as the company’s Chief Operations Officer. Thank you, Sierk for all you’ve done in your dual roles up to this point. Now I would like to hand over to Helmut Jeggle who will introduce Jens Holstein.